The CV values defined for each quasi-quantitative CSF tau peptide assay in AD CSF suggests that our assay will reliably detect ≥ 1.5 fold increases of tau peptide concentrations in dosed anti-tau subjects relative to baseline values. This evidence concerns the gene MAPT and Alzheimer disease.